Læknablaðið - 15.02.1993, Blaðsíða 20

62
LÆKNABLAÐIÐ
in serum concentrations are probably caused by
different methods and/or standards used by the two
groups of investigators. When compared to mean
serum values for apo A-I and apo B published
during the last 16 years by various investigators
from different countries, the present serum values
as well as the apo A-I/ apo B ratio, seem to be
among the higher ones (Table IV).
HEIMILDIR
1. Stein EA. Lipids, lipoprotein and apolipoproteins.
In: Tietz NW, ed. Textbook of clinical chemistry.
London: WB Saunders, 1986: 829-900.
2. Naito HK. Disorders of lipid metabolism. In: Kaplan
LA, Pesce AJ, eds. Clinical Chemistry. Theory,
analysis and correlation. Philadelphia: C.V. Mosby
1989: 454-83.
3. Nikkila E. Studies on the lipid-protein relationships
in normal and pathological sera and the effect of
heparin on serum lipoproteins. Scand J Clin Invest
1953; 5/Suppl. 8: 1-101.
4. Glueck CJ, Fallat RW, Millet F, Gartside P, Elston
RC, Go RCP. Familial hyper-alpha-lipoproteinemia:
studies in eighteen kindreds. Metabolism 1975; 24:
1243-65.
5. Colonna A, Agnotti E, Cavalconti E, Cortese C, Pujia
A, Mattioli PL. Serum apolipoprotein levels and early
atherosclerosis. Clin Chem 1991; 37: 926.
6. Walldius G, Jungner I, Kolar W, Steiner E.
Apolipoprotein B (apo B) as atherogenic risk
indicator in 30.565 subjects - Better than total serum
cholesterol. Clin Chem 1991; 37: 926.
7. Kottke BA, Zinsmeister AR, Holmes Jr DR, Kneller
RW, Hallaway BJ, Mao SJT. Apolipoproteins and
coronary artery disease. Mayo Clin Proc 1986; 661:
313-20.
8. Reinhart RA, Gani K, Amdt MR, Broste SK.
Apolipoprotiens A-1 and B as predictors of
angiographically defined coronary artery disease.
Arch Int Med 1990; 150: 1629-33:
9. Avogaro P, Bittolo Bon G, Cazzolato G, Quincy GB.
Are apolipoproteins better discriminators than lipids
for atherosclerosis. Lancet 1979; 1: 901-3.
10. Avogaro P, Bittolo Bon G, Cazzolato G, Quinci GB,
Belussi F. Plasma levels of apolipoprotein A1 and
apolipoprotein B in human atherosclerosis. Artery
1978; 4: 385-94.
11. Kukita H, Hiwada K, Kokubu T. Semm
Apolipoprotein A-I, A-II and B levels and their
discriminative values in relatives of patients with
coronary artery disease. Atherosclerosis 1984; 51:
261-7.
12. Sigurðsson G, Baldursdóttir Á, Sigvaldason H,
Agnarsson U, Thorgeirsson G, Sigfússon N.
Predictive value of apolipoproteins in a prospective
survey of coronary artery disease in men. Am J
Cardiol 1992; 69: 1251-4.
13. Brown G, Albers JJ, Fisher LD, et al. Regression
of coronary artery disease as a result of intensive
lipid-lowering therapy in men with high levels of
apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
14. Bachoric PS, Kwiterovich Jr PO. Apolipoprotein
measurements in clinical biochemistry and their
utility vis-a-vis conventioal assays. Clin Chim Acta
1988; 1778: 1-34.
15. Naito HK. The clinical significance of apolipoprotein
measurements. J Clin Immunoassays 1986; 9: 11-20.
16. Marcovina SM, Albers JJ, Dati F, Ledue TB,
Ritchie RF. Intemational Federation of Clinical
Chemistry standardization project for measurement
of apolipoproteins A-I and B. Clin Chem 1991; 37:
1676-82.
17. Sigfússon N, Sigvaldason H, Guðmundsdóttir
II, et al. Breytingar á tfðni kransæðastíflu og
kransæðadauðsfalla á íslandi. Tengsl við áhættuþætti
og mataræði. Læknablaðið 1991; 77: 49-58.
18. Sigfússon N, Sigvaldason H, Steingn'msdóttir L, et
al. Decline in ischemic heart disease in Iceland and
change in risk factor levels. Br Med J 1991; 302:
1371-5.
19. Þorgeirsson G, Davíðsson D, Sigvaldason H,
Sigfússon N. Áhættuþættir kransæðasjúkdóms
meðal karla og kvenna á Islandi. Niðurstöður úr
hóprannsókn Hjartavemdar 1967-1985. Læknablaðið
1992; 78: 267-76.
20. Sigurðsson Garðar, Baldursdóttir Á, Guðnason V,
Sigurðsson Gunnar. Þéttni fituprótína í íslendingum.
Læknablaðið 1992; 78: 172-9.
21. Friedewald WT, Levy RI, Fredricksson DS.
Estimation of the concentration of low-density
lipoprotein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem 1972; 18: 499-
502.
22. Wamick GR, Knopp RH, Fitzpatrick V, Branson L.
Estimating low-density lipoprotein cholesterol by
the Friedewald equation is adequate for classifying
patients on the basis of natioally recommended
cutpoints. Clin Chem 1990; 36: 15-9.
23. McNamara J, Cohn JS, Wilson PWF. Schaefer
EJ. Calculated values for low-density lipoprotein
cholesterol in the assessment of lipid abnormalities
and coronary disease risk. Clin Chem 1990; 36: 36-
42.
24. Armitage P, Berry G. Slatistical methods in medical
research. 2nd ed. London: Blackwell Scientific
Publications, 1987.
25. Lund RE. MSUSTAT - An interactive statistical
analysis package. The Research and Development
Institute Inc. 1983. Montana State University,
Bozeman, Montana.
26. Lehtonen A, Mamiemi J, Ingberg M, Maatela
J, Alanen E, Núttymaki K. Levels of semm
lipids, apolipoproteins Apo AI and B and
pseudocholinesterase activity and their discriminative
values in patients with coronary bypass operation.
Atherosclerosis 1986; 59: 215-21.
27. Kwiterovich PO, Sniderman AD. Atherosclerosis and
apolipoproteins A1 and B. Prev Med 1983; 12: 815-
34.
28. Kukita H, Hamada M, Hiwada K. Kokubu T. Clinical
significance of measurement of semm apolipoproteins
AI, AII, and aB in hypertriglyceridemic male
patients with and without coronary artery disease.
Atherosclerosis 1985; 55: 143-9.
29. DeBacker G, Rosseneau M, Deslypere JP.
Discriminative value of lipids and apolipoproteins
in coronary heart disease. Atheroslcerosis 1982; 42:
197-203.
30. Albers JJ, Cabana VG, Hazzard WR. Immunoassay
of human plasma apolipoprotein B. Metabolism 1975;
24: 1339-51.
31. Albers JJ, Wahl PW, Cabana VG, Hazzard WR,
Hoover JJ. Quantitation of apolipoprotein AI of
human plasma high density lipoprotein. Metabolism
1976; 25: 633-44.
32. Rifai N, King ME. Immunoturbidimetric assays of